Evidence map›Paper›PMID 40390585›Full record

ReviewJournal of Korean medical science2025

Antimicrobial Resistance - The 'Real' Pandemic We Are Unaware Of, Yet Nearby.

Jin-Hong Yoo

Abstract readReview
In one paragraph

Review in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jin-Hong YooDivision of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. jhyoo@catholic.ac.kr.ORCID https://orcid.org/0000-0003-2611-3399

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) represents a persistent and escalating public health crisis, often overlooked despite its severe global impact. Unlike acute infectious diseases, AMR progresses silently but relentlessly, posing long-term threats to health systems worldwide. This review examines the historical evolution and current epidemiology of multidrug-resistant organisms (MDROs), emphasizing the global and Korean burden of MDROs. While the development of new antibiotics remains limited, alternative therapies such as bacteriophage treatment have re-emerged as potential solutions. However, challenges in access to novel agents persist, particularly in Korea, due to regulatory, economic, and market-related barriers. To counter AMR, comprehensive strategies are essential. These include infection control, antibiotic stewardship programs (ASPs), and the development and proper allocation of new drugs. The One Health approach must integrate human, animal, and environmental health perspectives. Notably, infectious disease specialists play a central role in this fight: leading ASPs, shaping policy, engaging in public education, supporting research, and coordinating multidisciplinary collaboration. The AMR pandemic is unlikely to subside without systemic reform, sustained investment, and international cooperation. Urgent efforts must be made to address this hidden but growing threat. Recognizing AMR as a true pandemic is the first step toward containing its spread and securing the efficacy of antibiotics for future generations.

Indexed as

Anti-Bacterial AgentsPandemicsAnimalsAntimicrobial StewardshipDrug Resistance, Multiple, BacterialHumansRepublic of KoreaAnti-Bacterial AgentsAntibiotic Stewardship ProgramsAntimicrobial ResistanceInfection ControlMultidrug-Resistant Organisms (MDROs)

Identifiers

PMID40390585
PMCPMC12089690

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.